Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y3B4
UPID:
SF3B6_HUMAN
Alternative names:
Pre-mRNA branch site protein p14; SF3b 14 kDa subunit; Spliceosome-associated protein, 14-kDa; Splicing factor 3b, subunit 6, 14kDa
Alternative UPACC:
Q9Y3B4; Q53TM1
Background:
Splicing factor 3B subunit 6, known as Pre-mRNA branch site protein p14, plays a crucial role in pre-mRNA splicing as part of the SF3B complex. This protein is essential for the assembly of the 'A' complex, facilitating the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA. It directly interacts with the pre-mRNA branch site adenosine, critical for the first catalytic step of splicing.
Therapeutic significance:
Understanding the role of Splicing factor 3B subunit 6 could open doors to potential therapeutic strategies.